SCHEMBL6086199

SCHEMBL6086199

CC(=O)OC(C)C(=O)Nc1ccc(-c2n[nH]cc2-c2nc3ccc(C)cc3o2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.49
SMN1; SMN2 Q16637 7/20 0.49
POLB P06746 1/20 0.49
CETP P11597 2/20 0.48
AGPAT2 O15120 2/20 0.46
NPC1 O15118 7/20 0.45
RAB9A P51151 7/20 0.45
ALDH1A1 P00352 5/20 0.45
HSD17B10 Q99714 4/20 0.45
KMT2A Q03164 3/20 0.45
KDM4E B2RXH2 3/20 0.45
BAZ1A Q9NRL2 1/20 0.45
TP53 P04637 4/20 0.44
HPGD P15428 3/20 0.44
THRB P10828 3/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6084568 0.89 UTRN (0.47) SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10
SCHEMBL6085509 0.83 SMN1; SMN2 (0.63) MAPTSMN1; SMN2CETPAGPAT2NPC1
SCHEMBL6085581 0.81 MMP2 (0.52) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6085906 0.81 MAPT (0.53) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6086086 0.80 MAPT (0.50) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6086313 0.80 CETP (0.56) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6085303 0.80 MAPT (0.50) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6085257 0.80 POLB (0.48) MAPTPOLBNPC1RAB9AALDH1A1
SCHEMBL6642556 0.80 MAPT (0.41) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6085746 0.80 AGPAT2 (0.53) MAPTSMN1; SMN2POLBCETPAGPAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 MAPT 801/4885SMN1; SMN2 831/4885POLB 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.